A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
Public ClinicalTrials.gov record NCT06603246. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ic, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-obstructive Disease
Study identification
- NCT ID
- NCT06603246
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 128 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2024
- Primary completion
- Nov 14, 2027
- Completion
- Nov 14, 2027
- Last update posted
- May 4, 2026
2024 – 2027
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | Recruiting |
| Accel Research Site - Achieve - Birmingham - ERN - PPDS | Vestavia Hills | Alabama | 35216-1927 | Withdrawn |
| Stanford Center for Excellence in Pulmonary Biology | Palo Alto | California | 94304 | Recruiting |
| University of Kansas Medical Center-Kansas City-3901 Rainbow Blvd | Kansas City | Kansas | 66160 8500 | Recruiting |
| University of North Carolina Clinical Research Center | Chapel Hill | North Carolina | 27514 | Recruiting |
| UNC Investigational Drug Services | Morrisville | North Carolina | 27560 | Recruiting |
| TTS Research | Boerne | Texas | 78006 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Chronic Obstructive Pulmonary Disease trials
Other public records listing Chronic Obstructive Pulmonary Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT07512687: Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia Recruiting
- NCT06390345: Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention Recruiting
- NCT05399056: Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling Recruiting
- NCT05237505: The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome) Recruiting
- NCT07053423: A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. Recruiting
- NCT06208306: A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06603246, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06603246 live on ClinicalTrials.gov.